Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−27.28 USD
−16.86 M USD
4.58 M USD
3.07 M
About COSCIENS BIOPHARMA INC
COSCIENS Biopharma Inc. Is a specialty biopharmaceutical company, which engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Canada.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CSCI is 3.35 USD — it has decreased by −3.18% in the past 24 hours. Watch COSCIENS Biopharma Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange COSCIENS Biopharma Inc. stocks are traded under the ticker CSCI.
CSCI stock has fallen by −8.22% compared to the previous week, the month change is a −9.46% fall, over the last year COSCIENS Biopharma Inc. has showed a 120.41% increase.
CSCI reached its all-time high on Nov 24, 2015 with the price of 15.70 USD, and its all-time low was 0.04 USD and was reached on Oct 29, 2015. View more price dynamics on CSCI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CSCI stock is 8.63% volatile and has beta coefficient of 1.45. Track COSCIENS Biopharma Inc. stock price on the chart and check out the list of the most volatile stocks — is COSCIENS Biopharma Inc. there?
Today COSCIENS Biopharma Inc. has the market capitalization of 10.68 M, it has decreased by −2.36% over the last week.
Yes, you can track COSCIENS Biopharma Inc. financials in yearly and quarterly reports right on TradingView.
COSCIENS Biopharma Inc. is going to release the next earnings report on Nov 11, 2024. Keep track of upcoming events with our Earnings Calendar.
CSCI earnings for the last quarter are −0.64 USD per share, whereas the estimation was −3.28 USD resulting in a 80.49% surprise. The estimated earnings for the next quarter are −3.48 USD per share. See more details about COSCIENS Biopharma Inc. earnings.
COSCIENS Biopharma Inc. revenue for the last quarter amounts to 2.30 M USD, despite the estimated figure of 1.10 M USD. In the next quarter, revenue is expected to reach 1.10 M USD.
CSCI net income for the last quarter is −1.42 M USD, while the quarter before that showed −5.73 M USD of net income which accounts for 75.17% change. Track more COSCIENS Biopharma Inc. financial stats to get the full picture.
No, CSCI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 21.00 employees. See our rating of the largest employees — is COSCIENS Biopharma Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. COSCIENS Biopharma Inc. EBITDA is −20.10 M USD, and current EBITDA margin is −396.60%. See more stats in COSCIENS Biopharma Inc. financial statements.
Like other stocks, CSCI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade COSCIENS Biopharma Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So COSCIENS Biopharma Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating COSCIENS Biopharma Inc. stock shows the buy signal. See more of COSCIENS Biopharma Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.